MENU
+Compare
AKRO
Stock ticker: NASDAQ
AS OF
Jun 6, 04:59 PM (EDT)
Price
$54.28
Change
+$0.34 (+0.63%)
Capitalization
4.22B

AKRO Akero Therapeutics Forecast, Technical & Fundamental Analysis

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs... Show more

AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for AKRO with price predictions
Jun 05, 2025

Momentum Indicator for AKRO turns positive, indicating new upward trend

AKRO saw its Momentum Indicator move above the 0 level on May 20, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned positive. In of the 82 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for AKRO just turned positive on May 20, 2025. Looking at past instances where AKRO's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

AKRO moved above its 50-day moving average on May 20, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for AKRO crossed bullishly above the 50-day moving average on May 21, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AKRO advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 133 cases where AKRO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKRO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AKRO broke above its upper Bollinger Band on May 20, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AKRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.897) is normal, around the industry mean (16.332). P/E Ratio (0.000) is within average values for comparable stocks, (59.787). AKRO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.227). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (263.647).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

AKRO is expected to report earnings to rise 3.23% to -92 cents per share on August 08

Akero Therapeutics AKRO Stock Earnings Reports
Q2'25
Est.
$-0.93
Q1'25
Beat
by $0.11
Q4'24
Beat
by $0.17
Q3'24
Missed
by $0.17
Q2'24
Beat
by $0.02
The last earnings report on May 13 showed earnings per share of -89 cents, beating the estimate of -100 cents. With 531.28K shares outstanding, the current market capitalization sits at 4.22B.
A.I. Advisor
published General Information

General Information

a biotechnology company, which specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
601 Gateway Boulevard
Phone
+1 650 487-6488
Employees
56
Web
https://www.akerotx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IBUY68.800.06
+0.09%
Amplify Online Retail ETF
EFU11.12N/A
N/A
ProShares UltraShort MSCI EAFE
DEMZ37.41-0.04
-0.10%
Democratic Large Cap Core ETF
FISR25.44-0.04
-0.16%
SPDR® SSGA Fixed Inc Sect Rotation ETF
NVDY15.87-0.17
-1.06%
YieldMax NVDA Option Income Strategy ETF

AKRO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AKRO has been loosely correlated with ETNB. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if AKRO jumps, then ETNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKRO
1D Price
Change %
AKRO100%
+1.92%
ETNB - AKRO
60%
Loosely correlated
-0.99%
SLS - AKRO
41%
Loosely correlated
+1.87%
TRDA - AKRO
40%
Loosely correlated
+2.14%
IDYA - AKRO
39%
Loosely correlated
-0.09%
VTYX - AKRO
38%
Loosely correlated
+13.07%
More